간질환 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 질환별, 지역별, 부문별 예측(2024-2030년)

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Antiviral Drugs, Vaccines), By Disease (Hepatitis, Autoimmune Diseases, Cancer), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,311,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,708,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,502,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

간질환 치료제 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 간질환 치료제 시장은 2024년부터 2030년까지 5.7%의 CAGR을 기록하며 2030년까지 286억 2,000만 달러에 달할 것으로 예상됩니다.

주요 촉진요인은 간세포암과 같은 간질환의 증가와 이러한 유형의 질병 환자의 막대한 미개발 수요입니다. 또한, 전 세계 고령 인구의 증가는 향후 시장 수요를 증가시킬 것으로 추정됩니다.

생명공학 및 제약 업계의 연구개발에 대한 막대한 지출과 강력한 파이프라인의 가용성은 향후 간질환 치료제 시장의 성장을 촉진하는 주요 요인이 될 것으로 예상됩니다. 정부와 대기업의 백신 접종 프로그램은 질병과 예방에 대한 인식을 높이고 시장 성장을 촉진하고 있습니다.

시장은 제품과 지역으로 나뉩니다. 신제품이 빠르게 출시되면서 시장 성장을 촉진하고 있습니다. 시장 성장은 주요 기업 간의 전략적 제휴와 합작 투자, 그리고 향후 각국의 헬스케어에 대한 인식이 높아지면서 시장 성장을 견인하고 있습니다.

간질환 치료제 시장 보고서 하이라이트

• 세계 간질환 치료제 시장에서 항바이러스제 부문은 2023년 매출 점유율 30.3%로 시장을 주도하고 있습니다. 간염 질환의 높은 유병률이 간질환 환자 증가에 기여하고 있습니다.
• 표적치료제 부문은 전 세계 간질환 유병률 증가와 고령 인구 증가에 힘입어 예측 기간 동안 가장 빠른 CAGR 7.2%를 기록할 것으로 예상됩니다.
• 간염 부문은 2023년 36.6%의 매출 점유율로 세계 간질환 치료제 시장을 장악하고 있습니다.
• 비알코올성 지방간질환(NAFLD)은 예측 기간 동안 6.6%의 CAGR로 가장 빠른 성장을 기록할 것으로 예상됩니다. 이 부문의 성장은 비만 유병률 증가와 그에 따른 간세포의 지방 축적에 의해 촉진될 것입니다.
• 북미 간질환 치료제 시장은 2023년 38.4%의 매출 점유율로 세계 간질환 치료제 시장을 독점하고 있습니다.
• 아시아태평양 간질환 치료제 시장은 예측 기간 동안 연평균 7.4%의 가장 빠른 성장률을 보일 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 간질환 치료제 시장 변수, 동향, 범위

• 시장 소개/계통 전망
• 시장 규모와 성장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 간질환 치료제 시장 분석 툴
  • Porters 분석
  • PESTEL 분석

제4장 간질환 치료제 시장 : 약물 종류별 추정·동향 분석

• 부문 대시보드
• 간질환 치료제 시장 : 약물 종류별 변동 분석, 2023년 및 2030년
• 항바이러스제
• 백신
• 화학요법
• 표적요법
• 면역억제제
• 면역글로불린
• 코르티코스테로이드
• 기타 제품

제5장 간질환 치료제 시장 : 질환별 추정·동향 분석

• 부문 대시보드
• 간질환 치료제 시장 : 질환별 변동 분석, 2023년 및 2030년
• 간염
• 자가면역질환
• 비알코올성 지방간질환(NAFLD)
• 암
• 유전성 질환
• 기타 질병

제6장 간질환 치료제 시장 : 지역별 추정·동향 분석

• 간질환 치료제 시장 점유율, 지역별, 2023년 및 2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 상황

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업 분류
• 기업 히트맵 분석
• 기업 개요
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck &Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC

ksm

영문 목차

영문목차

Liver Disease Therapeutics Market Growth & Trends:

The global liver disease therapeutics market is expected to be valued at USD 28.62 billion by 2030, registering a CAGR of 5.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments' and big companies' vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Liver Disease Therapeutics Market Report Highlights:

• The antiviral drugs segment dominated the market in the global liver disease therapeutics market with a revenue share of 30.3% in 2023. The high incidence of hepatitis diseases contributes to the rise in liver disease cases.
• The targeted therapy segment is expected to register the fastest CAGR of 7.2% over the forecast period, driven by the rising incidence of liver diseases and geriatric population globally.
• The hepatitis segment dominated the global liver disease therapeutics market with a revenue share of 36.6% in 2023.
• Non-alcoholic fatty liver disease (NAFLD) is expected to register the fastest growth over the forecast period with a CAGR of 6.6%. Segment growth is fueled by the increasing prevalence of obesity and associated fat accumulation in liver cells.
• North America liver disease therapeutics market dominated the global liver disease therapeutics market with a revenue share of 38.4% in 2023.
• Asia Pacific liver disease therapeutics market is expected to have the fastest growth in the forecast period with a CAGR of 7.4%.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Liver Diseases Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
  • 3.3.3. Liver Diseases Therapeutics Market Analysis Tools
  • 3.3.4. Porter's Analysis
    • 3.3.4.1. Bargaining power of the suppliers
    • 3.3.4.2. Bargaining power of the buyers
    • 3.3.4.3. Threats of substitution
    • 3.3.4.4. Threats from new entrants
    • 3.3.4.5. Competitive rivalry
  • 3.3.5. PESTEL Analysis
    • 3.3.5.1. Political landscape
    • 3.3.5.2. Economic and Social landscape
    • 3.3.5.3. Technological landscape
    • 3.3.5.4. Environmental landscape
    • 3.3.5.5. Legal landscape

Chapter 4. Liver Disease Therapeutics Market: Drug Class Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Liver Disease Therapeutics Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
• 4.3. Antiviral Drugs
  • 4.3.1. Antiviral Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Vaccines
  • 4.4.1. Vaccines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Chemotherapy
  • 4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Targeted Therapy
  • 4.6.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Immunosuppressants
  • 4.7.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Immunoglobulins
  • 4.8.1. Immunoglobulins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Corticosteroids
  • 4.9.1. Corticosteroids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Other Products
  • 4.10.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liver Disease Therapeutics Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Liver Disease Therapeutics Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
• 5.3. Hepatitis
  • 5.3.1. Hepatitis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Autoimmune Diseases
  • 5.4.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Non-alcoholic Fatty Liver Disease (NAFLD)
  • 5.5.1. Non-alcoholic Fatty Liver Disease (NAFLD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Cancer
  • 5.6.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Genetic Disorders
  • 5.7.1. Genetic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Other Diseases
  • 5.8.1. Other Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liver Disease Therapeutics Market: Regional Estimates & Trend Analysis

• 6.1. Liver Disease Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
• 6.2. North America
  • 6.2.1. North America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. U.S. Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.3. Canada
    • 6.2.3.1. Canada Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.4. Mexico
    • 6.2.4.1. Mexico Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.3. Europe
  • 6.3.1. Europe Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. UK
    • 6.3.2.1. UK Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Germany
    • 6.3.3.1. Germany Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.4. France
    • 6.3.4.1. France Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.5. Italy
    • 6.3.5.1. Italy Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.6. Spain
    • 6.3.6.1. Spain Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.7. Denmark
    • 6.3.7.1. Denmark Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.8. Sweden
    • 6.3.8.1. Sweden Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.9. Norway
    • 6.3.9.1. Norway Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. China
    • 6.4.2.1. China Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Japan
    • 6.4.3.1. Japan Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. India
    • 6.4.4.1. India Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. South Korea
    • 6.4.5.1. South Korea Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. Australia
    • 6.4.6.1. Australia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.7. Thailand
    • 6.4.7.1. Thailand Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Brazil Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Argentina
    • 6.5.3.1. Argentina Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Middle East and Africa
  • 6.6.1. Middle East and Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. South Africa Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Saudi Arabia Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. UAE
    • 6.6.4.1. UAE Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Kuwait
    • 6.6.5.1. Kuwait Liver Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Heat Map Analysis
• 7.4. Company Profiles
  • 7.4.1. F. Hoffmann-La Roche Ltd
    • 7.4.1.1. Participant's Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Recent Developments/Strategic Initiatives
  • 7.4.2. Takeda Pharmaceutical Company Limited
    • 7.4.2.1. Participant's Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Recent Developments/Strategic Initiatives
  • 7.4.3. Gilead Sciences, Inc.
    • 7.4.3.1. Participant's Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Recent Developments/Strategic Initiatives
  • 7.4.4. Johnson & Johnson Services, Inc.
    • 7.4.4.1. Participant's Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Recent Developments/Strategic Initiatives
  • 7.4.5. Merck & Co., Inc.
    • 7.4.5.1. Participant's Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Recent Developments/Strategic Initiatives
  • 7.4.6. Novartis AG
    • 7.4.6.1. Participant's Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Recent Developments/Strategic Initiatives
  • 7.4.7. Pfizer Inc.
    • 7.4.7.1. Participant's Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Recent Developments/Strategic Initiatives
  • 7.4.8. Sanofi
    • 7.4.8.1. Participant's Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Recent Developments/Strategic Initiatives
  • 7.4.9. AbbVie Inc.
    • 7.4.9.1. Participant's Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Recent Developments/Strategic Initiatives
  • 7.4.10. Bristol-Myers Squibb Company
    • 7.4.10.1. Participant's Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Recent Developments/Strategic Initiatives
  • 7.4.11. GlaxoSmithKline PLC
    • 7.4.11.1. Participant's Overview
    • 7.4.11.2. Financial Performance
    • 7.4.11.3. Product Benchmarking
    • 7.4.11.4. Recent Developments/Strategic Initiatives

관련자료